Oncology’s Omnichannel Illusion

Oncology teams are pouring resources into omnichannel, yet very few are reaping the rewards. Fresh survey data from oncology brand leaders reveals the gap: 38% are actively deploying omnichannel tactics, yet only 5% rate them as optimized for impact. The simple truth is that while almost everyone is playing the game, hardly anyone feels they are playing it well. Dashboards buzz with activity, but fewer than half of leaders trust their agencies to prove marketing ROI, leaving teams chasing metrics that don't move the needle on prescriber behavior or market share.

This session will confront the problem head-on. Drawing on fresh survey data from oncology brand leaders;

• we’ll explore why performance theatre often masquerades as progress,
• why easy-to-capture metrics like clicks and opens obscure the harder questions of behaviour change and market impact.
• We will examine the barriers that hold teams back, including regulatory drag, attribution blind spots, fragmented technology and siloed execution—
• discuss what high-performing organisations are doing differently. We’ll also look at why AI adoption is gathering strength but isn’t necessarily solving the core problems we need to address.

If your slides look impressive but your strategy feels shallow, this session is the reset button you need. Expect a candid, data-rich conversation on how oncology teams can move beyond omnichannel activity to measurable, defensible impact.